Boehringer Ingelheim
3 stories
-
healthPharma Giants Invest £450M in UK, Boosting Innovation
AstraZeneca and Boehringer Ingelheim commit significant funds to UK expansion, focusing on research, AI, and new medicines.
-
healthBoehringer Ingelheim Obesity Drug Shows Significant Weight Loss in Phase 3 Trial
Boehringer Ingelheim's investigational obesity therapy, survodutide, achieved up to 16.6% average weight loss in a Phase 3 trial, targeting appetite and liver metabolism.
-
healthBoehringer Ingelheim Releases Critical Insights on HER2 Mutations for Professionals
New educational resource outlines HER2 mutation impacts on receptor signaling and oncogenesis for US healthcare practitioners.